The efficacy and safety of combination therapy with rosuvastatin + fenofibric acid were demonstrated in a 12-week controlled study ( NCT00300482 ) of patients with mixed dyslipidemia who were randomized to rosuvastatin 10 , 20 , or 40 mg , fenofibric acid 135 mg , or rosuvastatin 10 or 20 mg + fenofibric acid 135 mg .
